Skip to content
Get the Balanced News app for a better experience!
The Balanced News Logo
Analytics
The Balanced News Logo

Stay Balanced, Stay Informed

Menu
  • Browse News
  • Underreported Stories
  • Curated Feeds
  • Insights
  • Analytics
  • Our Writers
  • About Us
  • Download App
Learn
  • How It Works
  • Bias Detection
  • Lens Score
  • Source Bias Checker
  • Accountability
  • Custom Feeds
Newsroom
  • Writers & Analysts
  • About TBN
  • Editorial Standards
  • Corrections Policy
  • Our Partners
  • Insights
Socials
  • Youtube
  • Instagram
  • X
  • Facebook
News Categories
  • Trending
  • Politics
  • Sports
  • Business
  • Tech
  • Entertainment
  • Health
  • Science
  • Crime
  • Lifestyle
  • National
  • International
  • Good News
  • Crypto

Get Our App

Available for iOS and Android


LensFeedsInsightsAnalyticsTrendingGood NewsSportsPoliticsBusinessCrimeTechEntertainmentHealthNationalInternational

© 2026 The Balanced News. All rights reserved.

About UsEditorial StandardsCorrectionsHelp & SupportPrivacy PolicyTerms & Conditions
Government Revises Drug Price Control Order to Enhance Pricing Flexibility and Compliance

Categories

Categories

Related Coverage

Select a news story to see related coverage from other media outlets.

Related Coverage

Select a news story to see related coverage from other media outlets.

  1. Home
  2. /
  3. Business

Government Revises Drug Price Control Order to Enhance Pricing Flexibility and Compliance

Analysed 2 Jul 2026·3 sources analysed·India·Business
Government Revises Drug Price Control Order to Enhance Pricing Flexibility and CompliancePreviousNext

The Indian government has amended the Drugs (Prices Control) Order (DPCO), 2013, introducing changes that provide pharmaceutical companies greater flexibility in pricing essential medicines. The revisions allow varied ceiling prices based on packaging or dosage forms with therapeutic value and permit different prices for bulk buyers and retail consumers. Additionally, manufacturers' liability for overcharging is limited to stocks sold above notified prices by distributors or retailers if compliance with price communication is demonstrated, easing procedural burdens while strengthening documentation requirements.

TBN's observations

First-hand measurement across 3 sources

We measured how 3 outlets covered this story. Coverage leans balanced overall (Left 10%, Centre 80%, Right 10%). Overall sentiment is positive (67/100). Lens Score 34/100 — low public interest.

Outlets analysed (first-hand measurement by TBN's Bias Engine):

  • economictimes— balanced framing, positive sentiment
  • thefinancialexpress— balanced framing, neutral sentiment
  • businessstandard— balanced framing, neutral sentiment
Political Bias
10%80%10%
Sentiment
67%
AI analysis of 3 sources · Published under editorial oversight by The Balanced News
Analysed 2 Jul 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Political bias across 3 sources
● Left 10%● Center 80%● Right 10%

The articles present a largely neutral perspective focusing on regulatory changes without partisan framing. They include viewpoints from industry representatives highlighting benefits such as reduced procedural burdens and increased pricing freedom. There is no evident political positioning, with coverage centered on policy adjustments and their implications for pharmaceutical companies and regulators.

Sentiment — Positive (67/100)

The tone across the articles is generally positive or neutral, emphasizing the regulatory easing and increased flexibility for drug manufacturers. While acknowledging strengthened compliance measures, the coverage highlights benefits like reduced liability and pricing innovation, reflecting an overall constructive sentiment toward the amendments.

How 3 sources covered this story

Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.

Reviewed byMrunal Wange· Business & Economy Editor· Edited byOjas Kale
← Previous
Finkurve Financial Services Raises Rs 50 Crore via NCD Issuance from Franklin Templeton
Next →
Telecom Industry Debates Trai's Proposal on Satellite Infrastructure and Spectrum Allocation
SourceTheir headlineBiasSentiment
economictimesNew rules simplify drug launches, reduce manufacturer liability for overchargingCenterPositive
thefinancialexpressDrug companies get more pricing freedomCenterNeutral
businessstandardGovt tweaks DPCO to limit liability in overcharging cases, ease complianceCenterNeutral

Coverage timeline

businessstandard broke this story on 2 Jul, 01:41 pm. Other outlets followed.

  1. 1
    businessstandard2 Jul, 01:41 pm
    Govt tweaks DPCO to limit liability in overcharging cases, ease compliance
  2. 2
    thefinancialexpress2 Jul, 05:35 pm
    Drug companies get more pricing freedom
  3. 3
    economictimes2 Jul, 06:31 pm
    New rules simplify drug launches, reduce manufacturer liability for overcharging

Lens Score breakdown

34/100
Public interest0/100
Coverage gap100%

Well-covered story — coverage matches public importance.

Who's involved

Institutions and figures named across source coverage.

Government
Drug Prices Control OrderNational Pharmaceutical Pricing AuthorityCentral Government
Corporate
Indian Pharmaceutical AlliancePharmaceutical Companies

Story context

Category
Business
Location
India
Sources analysed
3
Last analysed
2 Jul 2026
Key entities
Pharmaceutical industryIndiaNational Pharmaceutical Pricing AuthorityPackaging and labelingElectric batterySupply chainRetailJainismEssential medicinesActive ingredientDosage formProcedural law